Codexis to Participate in Upcoming Healthcare Conferences
November 08 2022 - 4:05PM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company
enabling the promise of synthetic biology, today announced that
management will participate in three upcoming investor conferences.
The Stephens Annual Investment Conference on
November 15, 2022, at 2:00 p.m. ET in Nashville, Tennessee –
management will participate in an in-person fireside chat.
The Stifel 2022 Healthcare Conference on
November 16, 2022, at 1:50 p.m. ET in New York, New York –
management will participate in an in-person fireside chat.
The 13th Annual Craig-Hallum Alpha Select
Conference on November 17, 2022, in New York, New York – management
will attend and host 1x1 investor meetings.
Live webcasts of the Stephens and Stifel
fireside chats will be available on the Investor Relations section
of the Company’s website, http://ir.codexis.com. A replay of each
will be archived for 90 days following the presentation date.
About Codexis
Codexis is a leading enzyme engineering company
leveraging its proprietary CodeEvolver® platform to discover and
develop novel, high performance enzymes and biotherapeutics.
Codexis enzymes have applications in the sustainable manufacturing
of pharmaceuticals, food, and industrial products; in the creation
of the next generation of life science tools; and as gene therapy
and oral enzyme therapies. The Company’s unique performance enzymes
drive improvements such as: reduced energy usage, waste generation
and capital requirements; higher yields; higher fidelity
diagnostics; and more efficacious therapeutics. Codexis enzymes
enable the promise of synthetic biology to improve the health of
people and the planet. For more information, visit
www.codexis.com.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Codexis, they
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
You should not place undue reliance on these forward-looking
statements because they involve known and unknown risks,
uncertainties and other factors that are, in some cases, beyond
Codexis’ control and that could materially affect actual results.
Additional information about factors that could materially affect
actual results can be found in Codexis’ Annual Report on Form 10-K
filed with the Securities and Exchange Commission (“SEC”) on
February 28, 2022 and in Codexis’ Quarterly Report on Form 10-Q
filed with the SEC on November 4, 2022, including under the caption
“Risk Factors,” and in Codexis’ other periodic reports filed with
the SEC. Codexis expressly disclaims any intent or obligation to
update these forward-looking statements, except as required by
law.
Investor Relations Contact:
Argot PartnersBrendan Strong/Carrie McKim(212)
600-1902Codexis@argotpartners.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024